ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 123

Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis

Dax Rumsey1, Aimee Lougee 2, Roland Matsouaka 2, David Collier 3, Laura Schanberg 4, Jennifer Schenfeld 5, Natalie Shiff 6, Matthew Stoll 7, Scott Stryker 8, Pamela Weiss 9 and Timothy Beukelman 7 for the CARRA investigators, 1University of Alberta, Edmonton, Canada, 2Duke University, Durham, 3Amgen, Thousand Oaks, 4Duke Children's Hospital & Health Center, Durham, North Carolina, 5Amgen, Long Beach, 6Florida, Gainesville, 7University of Alabama at Birmingham, Birmingham, 8Amgen, Inc, San Francisco, 9Children's Hospital of Philadelphia, Philadelphia

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: Juvenile idiopathic arthritis-enthesitis (ERA), juvenile spondylarthropathy, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Saturday, May 2, 2020

Title: Poster Session 3

Session Type: ACR Abstract Session

Session Time: 4:15PM-5:15PM

Background/Purpose: To describe characteristics of children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry.

Methods: All children with ERA and JPsA were identified.  Demographics, clinical characteristics, and treatments were described.  Those with and without sacroiliitis were compared.  In those with sacroiliitis, the first visit with clinically active sacroiliitis was compared to the first visit without.

Results: Nine hundred two children with ERA or JPsA were identified.  Children with ERA were older at diagnosis (10.8 vs. 8.2 years) and more likely male (56% vs. 38%).  Polyarticular involvement was reported in 57% and 72% of those with ERA and JPsA.  Sacroiliitis was reported in 40% and 12% of those with ERA and JPsA.  HLA-B27 was positive in 38% and 12% of those with ERA and JPsA.  At least one biologic was taken by 72% and 64% of those with ERA and JPsA.

Twenty-eight percent of the children had sacroiliitis (diagnosed clinically and/or by imaging).  Of these, 54% were female, 36% were HLA-B27 positive, and 81% took at least one biologic.

In children with sacroiliitis, the physician global, parent/patient global, active joint count, and cJADAS 10 were all significantly worse during the first visit with clinically active sacroiliitis versus the first visit without.

Conclusion: In the CARRA Registry, there are over 900 children with ERA or JPsA.  There was high biologic use in this population, especially in those with sacroiliitis.  Further, there was equal sex representation in those with sacroiliitis.

Table 1: Characteristics of Children with Enthesitis Related Arthritis (ERA) or Psoriatic Arthritis (PsA) by JIA Category at the Most Recently Occurring Visit

Table 2: Characteristics of Children with Enthesitis Related Arthritis (ERA) or Psoriatic Arthritis (PsA) by Sacroiliitis Category (Ever Reported by Clinical Exam or Imaging)

Table 3: Characteristics of Children with Ever Reported Sacroiliitis at First Visit with Clinically Active Sacroiliitis Versus First Visit without Clinically Active Sacroiliitis


Disclosure: D. Rumsey, None; A. Lougee, None; R. Matsouaka, None; D. Collier, Amgen, Inc, 1, 2; L. Schanberg, Sanofi, 1, UCB, 1, Sobi, 1, 2, CARRA, 1, BMS, 1; J. Schenfeld, Amgen, Inc., 1, 2; N. Shiff, Abbvie, 1, 2, Novartis, 1, 2, Gliead, 1, 2, Mylan, 1, 2; M. Stoll, None; S. Stryker, Amgen, Inc, 1, 2, 3; P. Weiss, Lily, 1; T. Beukelman, UCB, 1, Novartis, 1.

To cite this abstract in AMA style:

Rumsey D, Lougee A, Matsouaka R, Collier D, Schanberg L, Schenfeld J, Shiff N, Stoll M, Stryker S, Weiss P, Beukelman T. Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/juvenile-spondyloarthritis-in-the-childhood-arthritis-and-rheumatology-research-alliance-carra-registry-high-biologic-use-low-prevalence-of-hla-b27-and-equal-sex-representation-in-those-with-sacr-2/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/juvenile-spondyloarthritis-in-the-childhood-arthritis-and-rheumatology-research-alliance-carra-registry-high-biologic-use-low-prevalence-of-hla-b27-and-equal-sex-representation-in-those-with-sacr-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology